Litcius/Paper detail

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Byeong‐Keuk Kim, Sung‐Jin Hong, Yong‐Joon Lee, Soon Jun Hong, Kyeong Ho Yun, Bum‐Kee Hong, Jung Ho Heo, Seung‐Woon Rha, Yun‐Hyeong Cho, Seung‐Jun Lee, Chul‐Min Ahn, Jung‐Sun Kim, Young‐Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong‐Ki Hong

2022The Lancet307 citationsDOIOpen Access PDF

Topics & Concepts

MedicineEzetimibeStatinRosuvastatinInternal medicineClinical endpointCombination therapyAdverse effectPopulationRandomized controlled trialClinical trialEnvironmental healthLipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAtherosclerosis and Cardiovascular Diseases
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial | Litcius